Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017
CRANBURY, N.J., Feb. 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2016. Recent Highlights Rekynda (bremelanotide) – Under development for Hypoactive Sexual Desire …